Exclusive: Enanta Pharmaceuticals CEO Jay Luly Discusses Hep C Pipeline
July 03, 2014 at 09:39 AM EDT
The hepatitis C industry has been on fire since Merck (NYSE: MRK) paid a 230 percent premium for pharmaceutical company Idenix (NASDAQ: ...